We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Sickle Cell Disease, Hemechip

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03948516
Recruitment Status : Completed
First Posted : May 14, 2019
Last Update Posted : May 26, 2022
US federal government
Amino Kano Teaching Hospital
Murtala Mohammed Specialist Hospital
Hasiya Bayero Pediatric Hospital
University of Nebraska
University of North Carolina, Chapel Hill
Case Western Reserve University
Information provided by (Responsible Party):
AOwusu-Ansah, University Hospitals Cleveland Medical Center

Brief Summary:
Sickle cell disease is very common in Nigeria. Early diagnosis is important to prevent or reduce serious complications from the disease and to enable children stay healthy. To this end, the investigators would like to test a new, simple and quick device called the HemeChip to determine if it can detect whether or not someone has sickle cell disease. The investigators will compare the results obtained with the HemeChip with a standard method of diagnosing sickle cell disease known as Isoelectric focusing (IEF) or High Performance Liquid Chromatography (HPLC).If the investigators show that the new device can differentiate between children who have sickle cell disease and those who don't as successfully as the IEF or HPLC, they estimate a sharp increase in the use of this device in many countries especially in Africa due to its lower cost

Condition or disease
Sickle Cell Disease

Detailed Description:

Sickle cell disease (SCD) is a group of inherited disorders of haemoglobin (Hb) synthesis, first described in the medical literature by James Herrick in 1910. Each year about 300,000 infants are born with SCD, including more than 200,000 cases in subSaharan Africa alone. In Nigeria alone, there are over 150,000 of these children born annually and it is estimated that between 50-90% of these children die before their fifth birthday. Overall, in the region, 6% of all childhood mortality in children less than 5 years of age is due to SCD complications and infections. Vaso occlusive crisis and anemia are serious complications of SCD, with infection often being the major cause of hospitalizations, crisis and death. SCD is caused by a point mutation in the sixth codon of the beta globin chain that produces normal Hb (HbA). This substitution of hydrophilic glutamic acid with hydrophobic valine produces sickle Hb (HbS), which is abnormally polymerized at low oxygen conditions causing sickling. Abnormal polymerization of HbS affects red cell membrane properties, shape, and density, and subsequent critical changes in inflammatory cell and endothelial cell function.

The clinical consequences of SCD include painful crises, widespread organ damage, and early mortality. Current standard practices for diagnosing SCD are high performance liquid chromatography (HPLC) and bench-top Hb electrophoresis. These two approaches, however, require trained personnel and state-of-the-art facilities, both of which may be lacking in many parts of sub-Saharan Africa where the disease is most prevalent.

These laboratory methods also carry significant costs which may be unaffordable for most patients. HemeChip diagnostic system offers an original and innovative solution, leveraging a novel engineering approach, to point of care (POC) diagnosis of SCD. HemeChip separates haemoglobin protein types in a miniscule volume of blood (1μL) on a piece of cellulose acetate paper that is housed in a micro-engineered chip with a controlled environment and electric field. Differences in Hb mobilities allow separation to occur within the cellulose acetate paper. A micro-engineered design and multiple layer lamination approach are utilized in fabricating the HemeChip. The design allows rapid manual assembly and results are available within a few minutes of performing the test.

HemeChip can also integrate with a mobile user interface (e.g. IPhone, IPod), which shows the test result quantitatively and objectively on the screen. HemeChip can be used by anyone after a short (30 minute) training, eliminating the need for highly skilled personnel.

Layout table for study information
Study Type : Observational
Actual Enrollment : 738 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Validation of a Point-of-care Screening Tool for Children With Sickle Cell Disease
Actual Study Start Date : July 11, 2017
Actual Primary Completion Date : April 26, 2018
Actual Study Completion Date : April 26, 2018

Resource links provided by the National Library of Medicine

Participants tested for Sickle cell disease

Primary Outcome Measures :
  1. Validation of the HemeChip technology as a novel, point-of-care (POC) platform for screening SCD. [ Time Frame: 30 minutes ]
    The results obtained using the HemeChip will be compared to High Performance Liquid Chromatography (HPLC), and the sensitivity and specificity of the HemeChip will be determined.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Weeks to 60 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Infants and children aged 6 weeks to 60 months

Inclusion Criteria:

  • Fever or hypothermia (Temp ≥38 C or ≤36 C) Plus one of the following (prostration, excessive crying, poor feeding, altered consciousness, convulsion, difficulty breathing, profuse vomiting, diarrhea) & rapid breathing (0-2months>60 breaths/min, 3-12months >50 breaths/min, 13- 59 months > 40 breaths /min)
  • Provision of signed and dated written informed consent by parent or guardian

Exclusion Criteria:

  • Parent of child chooses to opt out of the study after initial consent.
  • Blood transfusion within 3 months of study enrollment.
  • Presence of condition or abnormality that in the opinion of the investigator would compromise the safety of the child or the quality of the data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03948516

Layout table for location information
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, North Carolina
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
United States, Ohio
Case Western Reserve University
Cleveland, Ohio, United States, 44106
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Aminu Kano Teaching Hospital
Kano, Nigeria
Hasiya Bayero Pediatric Hospital
Kano, Nigeria
Murtala Mohammed Specialist Hospital
Kano, Nigeria
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
US federal government
Amino Kano Teaching Hospital
Murtala Mohammed Specialist Hospital
Hasiya Bayero Pediatric Hospital
University of Nebraska
University of North Carolina, Chapel Hill
Case Western Reserve University
  Study Documents (Full-Text)

Documents provided by AOwusu-Ansah, University Hospitals Cleveland Medical Center:
Layout table for additonal information
Responsible Party: AOwusu-Ansah, Physician, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier: NCT03948516    
Other Study ID Numbers: 04-17-15
First Posted: May 14, 2019    Key Record Dates
Last Update Posted: May 26, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hematologic Diseases
Genetic Diseases, Inborn